Pfizer Pipeline | Key Anticipated 2026 Catalysts

1. Achieved in late 2025; 1L=First-line; 1-2L=First- or second-line; 2L+=Second-line plus; HRRm=Homologous recombination repair mutant; TPS=Tumor proportion score

*Includes VESPER-4 study of ultra-long-acting GLP-1 for weekly chronic weight management in participants with obesity or overweight and without Type 2 diabetes mellitus (achieved first subject first dose in late 2025), VESPER-5 study of ultra-long-acting GLP-1 for weekly chronic weight management in participants with obesity or overweight and Type 2 diabetes mellitus, VESPER-6 study of ultra-long-acting GLP-1 for monthly chronic weight management, and seven additional studies of MET-097i.

This list is not inclusive of all ongoing programs in Pfizer’s product pipeline and inclusion in this list does not guarantee continued investment. Catalyst descriptions are intended to be high-level and may present disease area rather than indication. Data readout completion does not imply that any or all endpoints of the study were met. Data readouts are Phase 3 unless otherwise noted. Listed pivotal studies may include those that are Phase 3, Phase 4, or potentially registration-enabling Phase 2 or 2/3 studies. Some pivotal study starts, which are defined by first subject first dose (FSFD), may be subject, among other things, to data generation in earlier-stage studies and/or alignment with regulatory agencies. Many clinical research studies are event driven and readouts are therefore subject to change. Pfizer assumes no obligation to update this information in response to new or future developments. Please see Pfizer's SEC filings, press releases and other disclosures for additional information.